Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 3,746,000 shares, an increase of 30.9% from the May 30th total of 2,860,700 shares. Based on an average daily trading volume, of 446,300 shares, the days-to-cover ratio is currently 8.4 days. Currently, 7.9% of the shares of the company are sold short.
In related news, Director John B. Landis acquired 40,000 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average cost of $1.74 per share, for a total transaction of $69,600.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 18.91% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in EYPT. BlackRock Inc. increased its holdings in shares of Eyepoint Pharmaceuticals by 712.5% during the 4th quarter. BlackRock Inc. now owns 1,232,335 shares of the company’s stock valued at $2,329,000 after purchasing an additional 1,080,662 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Eyepoint Pharmaceuticals by 78.5% in the 4th quarter. Bank of New York Mellon Corp now owns 51,501 shares of the company’s stock worth $97,000 after acquiring an additional 22,645 shares in the last quarter. Northern Trust Corp increased its holdings in Eyepoint Pharmaceuticals by 10.8% in the 4th quarter. Northern Trust Corp now owns 113,544 shares of the company’s stock worth $215,000 after acquiring an additional 11,064 shares in the last quarter. Geode Capital Management LLC increased its holdings in Eyepoint Pharmaceuticals by 33.4% in the 4th quarter. Geode Capital Management LLC now owns 417,597 shares of the company’s stock worth $789,000 after acquiring an additional 104,582 shares in the last quarter. Finally, Barclays PLC purchased a new stake in Eyepoint Pharmaceuticals in the 4th quarter worth $474,000. Institutional investors own 58.29% of the company’s stock.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 195.83% and a negative net margin of 1,739.81%. The business had revenue of $2.01 million for the quarter, compared to analyst estimates of $3.70 million. On average, analysts anticipate that Eyepoint Pharmaceuticals will post -0.4 earnings per share for the current year.
A number of brokerages recently commented on EYPT. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research note on Thursday, March 21st. HC Wainwright upped their price objective on Palatin Technologies from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Finally, Zacks Investment Research downgraded Hess Midstream Partners from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.
See Also: Stock Symbols and CUSIP Explained
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.